{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T19:11:32Z","timestamp":1768677092044,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["105-2321-B-002-036; 106-2321-B-002-011; 107-2321-B-002-002"],"award-info":[{"award-number":["105-2321-B-002-036; 106-2321-B-002-011; 107-2321-B-002-002"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["108-2321-B-002-028"],"award-info":[{"award-number":["108-2321-B-002-028"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TheVax Genetics Vaccine Company Limited"},{"DOI":"10.13039\/501100007647","name":"College of Medicine, National Taiwan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007647","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hepatitis B virus (HBV) persistently infected about 250 million people worldwide, and a curative treatment remains an unmet medical need. Among many approaches to treat chronic hepatitis B (CHB), therapeutic vaccines have been developed for two decades, but none have yielded promising results in clinical trials. Therefore, dissection of HBV clearance mechanisms during therapeutic vaccination in appropriate models, which could give rise to new curative therapies, is urgently needed. Growing evidence indicates that prolonged and intensive exposure of antigen-specific T cells to viral antigens is a major cause of T cell exhaustion, and decreases anti-HBV immunity efficacy of therapeutic vaccination. HBV X protein (HBx) is expressed at low levels, and the understanding of its immunogenicity and potential in therapeutic CHB vaccines is limited.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>HBV genome sequences from CHB patients were cloned into a pAAV plasmid backbone and transfected into immunocompetent mouse hepatocytes through hydrodynamic injection. Mice carrying &gt;\u2009500\u2009IU\/mL serum HBV surface antigen (HBs) for more than 4\u2009weeks were considered HBV carriers mimicking human CHB and received 3 doses of weekly HBx vaccine by subcutaneous immunization. Serum HBV clearance was evaluated by monitoring serum HBs and HBV-DNA titers. Residual HBV in the liver was evaluated by western blotting for HBV core antigen. The splenic antigen-specific T cell response was quantified by a 15-mer overlapping peptide-stimulated interferon-\u03b3 enzyme-linked immunospot assay. Blood and hepatic immune cells were quantified by flow cytometric analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our HBx-based vaccine induced systemic HBx-specific CD4<jats:sup>+<\/jats:sup> and CD8<jats:sup>+<\/jats:sup> T cell responses in HBV carrier mice and demonstrated significant HBs and HBV-DNA elimination. The protective effect persisted for at least 30\u2009days without additional booster immunization. Different infiltrating myeloid cell subsets, each with distinctive roles during immune-mediated HBV clearance, were found in the liver of vaccinated mice. During vaccine therapy, inflammatory monocyte depletion resulted in sustained HBV clearance inhibition, whereas phagocytic monocyte-derived macrophage and Kupffer cell elimination resulted in only transient inhibition of vaccine-induced HBV clearance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We report the potential role of HBx as a major immunogen in an HBV therapeutic vaccine and the significance of a liver-infiltrating monocyte subset during hepatic viral clearance.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12929-020-00662-x","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T14:03:24Z","timestamp":1590674604000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["HBV X protein-based therapeutic vaccine accelerates viral antigen clearance by mobilizing monocyte infiltration into the liver in HBV carrier mice"],"prefix":"10.1186","volume":"27","author":[{"given":"Jau-Hau","family":"Horng","sequence":"first","affiliation":[]},{"given":"Wei-Hsiang","family":"Lin","sequence":"additional","affiliation":[]},{"given":"Chang-Ru","family":"Wu","sequence":"additional","affiliation":[]},{"given":"You-Yu","family":"Lin","sequence":"additional","affiliation":[]},{"given":"Li-Ling","family":"Wu","sequence":"additional","affiliation":[]},{"given":"Ding-Shinn","family":"Chen","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8316-3785","authenticated-orcid":false,"given":"Pei-Jer","family":"Chen","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"key":"662_CR1","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1128\/JVI.02844-06","volume":"81","author":"C Boni","year":"2007","unstructured":"Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol. 2007;81:4215\u201325.","journal-title":"J Virol"},{"key":"662_CR2","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.jhep.2014.07.005","volume":"61","author":"B Bengsch","year":"2014","unstructured":"Bengsch B, Martin B, Thimme R. Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J Hepatol. 2014;61:1212\u20139.","journal-title":"J Hepatol"},{"key":"662_CR3","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1136\/gutjnl-2018-316641","volume":"68","author":"A Schuch","year":"2019","unstructured":"Schuch A, Salimi Alizei E, Heim K, Wieland D, Kiraithe MM, Kemming J, et al. Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load. Gut. 2019;68:905\u201315.","journal-title":"Gut."},{"key":"662_CR4","doi-asserted-by":"publisher","first-page":"4588","DOI":"10.1172\/JCI121960","volume":"128","author":"AR Burton","year":"2018","unstructured":"Burton AR, Pallett LJ, McCoy LE, Suveizdyte K, Amin OE, Swadling L, et al. Circulating and intrahepatic antiviral B cells are defective in hepatitis B. J Clin Invest. 2018;128:4588\u2013603.","journal-title":"J Clin Invest"},{"key":"662_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1053\/j.gastro.2018.10.032","volume":"156","author":"AJ Gehring","year":"2019","unstructured":"Gehring AJ, Protzer U. Targeting innate and adaptive immune responses to cure chronic HBV infection. Gastroenterology. 2019;156:325\u201337.","journal-title":"Gastroenterology."},{"key":"662_CR6","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S2468-1253(18)30007-4","volume":"3","author":"MK Maini","year":"2018","unstructured":"Maini MK, Pallett LJ. Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand. Lancet Gastroenterol Hepatol. 2018;3:192\u2013202.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"662_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1053\/j.gastro.2019.03.044","volume":"157","author":"C Boni","year":"2019","unstructured":"Boni C, Janssen HLA, Rossi M, Yoon SK, Vecchi A, Barili V, et al. Combined GS-4774 and tenofovir therapy can improve HBV-specific T-cell responses in patients with chronic hepatitis. Gastroenterology. 2019;157:227\u201341 e7.","journal-title":"Gastroenterology"},{"key":"662_CR8","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.3389\/fimmu.2019.02308","volume":"10","author":"Z Ma","year":"2019","unstructured":"Ma Z, Zhang E, Gao S, Xiong Y, Lu M. Toward a functional cure for hepatitis B: the rationale and challenges for therapeutic targeting of the B cell immune response. Front Immunol. 2019;10:2308.","journal-title":"Front Immunol"},{"key":"662_CR9","doi-asserted-by":"publisher","first-page":"8623","DOI":"10.1073\/pnas.0809818106","volume":"106","author":"SN Mueller","year":"2009","unstructured":"Mueller SN, Ahmed R. High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A. 2009;106:8623\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"662_CR10","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1084\/jem.20150598","volume":"213","author":"DT Utzschneider","year":"2016","unstructured":"Utzschneider DT, Alfei F, Roelli P, Barras D, Chennupati V, Darbre S, et al. High antigen levels induce an exhausted phenotype in a chronic infection without impairing T cell expansion and survival. J Exp Med. 2016;213:1819\u201334.","journal-title":"J Exp Med"},{"key":"662_CR11","doi-asserted-by":"publisher","first-page":"E2540","DOI":"10.1073\/pnas.1406674111","volume":"111","author":"SS Tay","year":"2014","unstructured":"Tay SS, Wong YC, McDonald DM, Wood NA, Roediger B, Sierro F, et al. Antigen expression level threshold tunes the fate of CD8 T cells during primary hepatic immune responses. Proc Natl Acad Sci U S A. 2014;111:E2540\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"662_CR12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.coviro.2018.04.003","volume":"30","author":"C Dembek","year":"2018","unstructured":"Dembek C, Protzer U, Roggendorf M. Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination. Curr Opin Virol. 2018;30:58\u201367.","journal-title":"Curr Opin Virol"},{"key":"662_CR13","doi-asserted-by":"publisher","first-page":"12725","DOI":"10.1128\/JVI.78.23.12725-12734.2004","volume":"78","author":"MJ Bouchard","year":"2004","unstructured":"Bouchard MJ, Schneider RJ. The enigmatic X gene of hepatitis B virus. J Virol. 2004;78:12725\u201334.","journal-title":"J Virol"},{"key":"662_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169648","volume":"12","author":"C Niu","year":"2017","unstructured":"Niu C, Livingston CM, Li L, Beran RK, Daffis S, Ramakrishnan D, et al. The Smc5\/6 complex restricts HBV when localized to ND10 without inducing an innate immune response and is counteracted by the HBV X protein shortly after infection. PLoS One. 2017;12:e0169648.","journal-title":"PLoS One"},{"key":"662_CR15","doi-asserted-by":"publisher","first-page":"e101904","DOI":"10.1371\/journal.pone.0101904","volume":"9","author":"TH King","year":"2014","unstructured":"King TH, Kemmler CB, Guo Z, Mann D, Lu Y, Coeshott C, et al. A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance. PLoS One. 2014;9:e101904.","journal-title":"PLoS One"},{"key":"662_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1146\/annurev.immunol.021908.132629","volume":"27","author":"IN Crispe","year":"2009","unstructured":"Crispe IN. The liver as a lymphoid organ. Annu Rev Immunol. 2009;27:147\u201363.","journal-title":"Annu Rev Immunol"},{"key":"662_CR17","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/nri2858","volume":"10","author":"AW Thomson","year":"2010","unstructured":"Thomson AW, Knolle PA. Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol. 2010;10:753\u201366.","journal-title":"Nat Rev Immunol"},{"key":"662_CR18","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/ni.2573","volume":"14","author":"LR Huang","year":"2013","unstructured":"Huang LR, Wohlleber D, Reisinger F, Jenne CN, Cheng RL, Abdullah Z, et al. Intrahepatic myeloid-cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection. Nat Immunol. 2013;14:574\u201383.","journal-title":"Nat Immunol"},{"key":"662_CR19","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.ymthe.2017.06.018","volume":"25","author":"M Cebula","year":"2017","unstructured":"Cebula M, Riehn M, Hillebrand U, Kratzer RF, Kreppel F, Koutsoumpli G, et al. TLR9-mediated conditioning of liver environment is essential for successful intrahepatic immunotherapy and effective memory recall. Mol Ther. 2017;25:2289\u201398.","journal-title":"Mol Ther"},{"key":"662_CR20","doi-asserted-by":"publisher","first-page":"17862","DOI":"10.1073\/pnas.0608578103","volume":"103","author":"LR Huang","year":"2006","unstructured":"Huang LR, Wu HL, Chen PJ, Chen DS. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci U S A. 2006;103:17862\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"662_CR21","doi-asserted-by":"publisher","first-page":"9089","DOI":"10.1158\/0008-5472.CAN-05-0958","volume":"65","author":"CW Liao","year":"2005","unstructured":"Liao CW, Chen CA, Lee CN, Su YN, Chang MC, Syu MH, et al. Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects. Cancer Res. 2005;65:9089\u201398.","journal-title":"Cancer Res"},{"key":"662_CR22","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1002\/hep.30476","volume":"69","author":"LL Wu","year":"2019","unstructured":"Wu LL, Peng WH, Wu HL, Miaw SC, Yeh SH, Yang HC, et al. Lymphocyte antigen 6 complex, locus C+ monocytes and Kupffer cells orchestrate liver immune responses against hepatitis B virus in mice. Hepatology. 2019;69:2364\u201380.","journal-title":"Hepatology."},{"key":"662_CR23","volume":"1","author":"J Zhu","year":"2016","unstructured":"Zhu J, Chen H, Huang X, Jiang S, Yang Y. Ly6Chi monocytes regulate T cell responses in viral hepatitis. JCI Insight. 2016;1:e89880.","journal-title":"JCI Insight"},{"key":"662_CR24","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1136\/gutjnl-2017-315588","volume":"68","author":"HJ Zhao","year":"2019","unstructured":"Zhao HJ, Han QJ, Wang G, Lin A, Xu DQ, Wang YQ, et al. Poly I:C-based rHBVvac therapeutic vaccine eliminates HBV via generation of HBV-specific CD8+ effector memory T cells. Gut. 2019;68:2032\u201343.","journal-title":"Gut."},{"key":"662_CR25","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/hep.26654","volume":"59","author":"S Lv","year":"2014","unstructured":"Lv S, Wang J, Dou S, Yang X, Ni X, Sun R, et al. Nanoparticles encapsulating hepatitis B virus cytosine-phosphate-guanosine induce therapeutic immunity against HBV infection. Hepatology. 2014;59:385\u201394.","journal-title":"Hepatology."},{"key":"662_CR26","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1073\/pnas.1424775112","volume":"112","author":"HH Chou","year":"2015","unstructured":"Chou HH, Chien WH, Wu LL, Cheng CH, Chung CH, Horng JH, et al. Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota. Proc Natl Acad Sci U S A. 2015;112:2175\u201380.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"662_CR27","doi-asserted-by":"publisher","first-page":"7672","DOI":"10.4049\/jimmunol.0902874","volume":"183","author":"D Rai","year":"2009","unstructured":"Rai D, Pham NL, Harty JT, Badovinac VP. Tracking the total CD8 T cell response to infection reveals substantial discordance in magnitude and kinetics between inbred and outbred hosts. J Immunol. 2009;183:7672\u201381.","journal-title":"J Immunol"},{"key":"662_CR28","doi-asserted-by":"publisher","first-page":"9266","DOI":"10.1128\/JVI.00608-12","volume":"86","author":"YJ Lin","year":"2012","unstructured":"Lin YJ, Wu HL, Chen DS, Chen PJ. Hepatitis B virus nucleocapsid but not free core antigen controls viral clearance in mice. J Virol. 2012;86:9266\u201373.","journal-title":"J Virol"},{"key":"662_CR29","doi-asserted-by":"publisher","first-page":"e00248","DOI":"10.1128\/JVI.00248-19","volume":"93","author":"D Kornyeyev","year":"2019","unstructured":"Kornyeyev D, Ramakrishnan D, Voitenleitner C, Livingston CM, Xing W, Hung M, et al. Spatiotemporal analysis of hepatitis B virus X protein in primary human hepatocytes. J Virol. 2019;93:e00248\u201319.","journal-title":"J Virol"},{"key":"662_CR30","doi-asserted-by":"publisher","first-page":"10808","DOI":"10.1038\/s41598-019-47149-w","volume":"9","author":"AD Kosinska","year":"2019","unstructured":"Kosinska AD, Moeed A, Kallin N, Festag J, Su J, Steiger K, et al. Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection. Sci Rep. 2019;9:10808.","journal-title":"Sci Rep"},{"key":"662_CR31","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1016\/j.vaccine.2015.03.079","volume":"33","author":"J Li","year":"2015","unstructured":"Li J, Ge J, Ren S, Zhou T, Sun Y, Sun H, et al. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection. Vaccine. 2015;33:4247\u201354.","journal-title":"Vaccine."},{"key":"662_CR32","doi-asserted-by":"publisher","first-page":"6670","DOI":"10.4049\/jimmunol.0803683","volume":"182","author":"BO Lee","year":"2009","unstructured":"Lee BO, Tucker A, Frelin L, Sallberg M, Jones J, Peters C, et al. Interaction of the hepatitis B core antigen and the innate immune system. J Immunol. 2009;182:6670\u201381.","journal-title":"J Immunol"},{"key":"662_CR33","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1172\/JCI200421087","volume":"113","author":"G Sitia","year":"2004","unstructured":"Sitia G, Isogawa M, Iannacone M, Campbell IL, Chisari FV, Guidotti LG. MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. J Clin Invest. 2004;113:1158\u201367.","journal-title":"J Clin Invest"},{"key":"662_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002061","volume":"7","author":"G Sitia","year":"2011","unstructured":"Sitia G, Iannacone M, Aiolfi R, Isogawa M, van Rooijen N, Scozzesi C, et al. Kupffer cells hasten resolution of liver immunopathology in mouse models of viral hepatitis. PLoS Pathog. 2011;7:e1002061.","journal-title":"PLoS Pathog"},{"key":"662_CR35","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.immuni.2018.10.005","volume":"49","author":"M Guilliams","year":"2018","unstructured":"Guilliams M, Mildner A, Yona S. Developmental and functional heterogeneity of monocytes. Immunity. 2018;49:595\u2013613.","journal-title":"Immunity."},{"key":"662_CR36","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.1128\/JVI.03733-14","volume":"89","author":"D Movita","year":"2015","unstructured":"Movita D, van de Garde MD, Biesta P, Kreefft K, Haagmans B, Zuniga E, et al. Inflammatory monocytes recruited to the liver within 24 hours after virus-induced inflammation resemble Kupffer cells but are functionally distinct. J Virol. 2015;89:4809\u201317.","journal-title":"J Virol"},{"key":"662_CR37","doi-asserted-by":"publisher","first-page":"5986","DOI":"10.1038\/s41598-017-06236-6","volume":"7","author":"S De Koker","year":"2017","unstructured":"De Koker S, Van Hoecke L, De Beuckelaer A, Roose K, Deswarte K, Willart MA, et al. Inflammatory monocytes regulate Th1 oriented immunity to CpG adjuvanted protein vaccines through production of IL-12. Sci Rep. 2017;7:5986.","journal-title":"Sci Rep"},{"key":"662_CR38","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.4049\/jimmunol.169.8.4279","volume":"169","author":"KB Nguyen","year":"2002","unstructured":"Nguyen KB, Salazar-Mather TP, Dalod MY, Van Deusen JB, Wei XQ, Liew FY, et al. Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. J Immunol. 2002;169:4279\u201387.","journal-title":"J Immunol"},{"key":"662_CR39","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/hep.29239","volume":"66","author":"Y Bian","year":"2017","unstructured":"Bian Y, Zhang Z, Sun Z, Zhao J, Zhu D, Wang Y, et al. Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice. Hepatology. 2017;66:1067\u201382.","journal-title":"Hepatology."},{"key":"662_CR40","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1053\/j.gastro.2012.03.006","volume":"142","author":"LR Huang","year":"2012","unstructured":"Huang LR, Gabel YA, Graf S, Arzberger S, Kurts C, Heikenwalder M, et al. Transfer of HBV genomes using low doses of adenovirus vectors leads to persistent infection in immune competent mice. Gastroenterology. 2012;142:1447\u201350 e3.","journal-title":"Gastroenterology"},{"key":"662_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039179","volume":"7","author":"HT Tzeng","year":"2012","unstructured":"Tzeng HT, Tsai HF, Liao HJ, Lin YJ, Chen L, Chen PJ, et al. PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model. PLoS One. 2012;7:e39179.","journal-title":"PLoS One"}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-020-00662-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12929-020-00662-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-020-00662-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:39:31Z","timestamp":1622162371000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbiomedsci.biomedcentral.com\/articles\/10.1186\/s12929-020-00662-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["662"],"URL":"https:\/\/doi.org\/10.1186\/s12929-020-00662-x","relation":{},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,28]]},"assertion":[{"value":"19 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiment protocols were approved by the Institutional Animal Care and Use Committee (IACUC) at the National Taiwan University College of Medicine.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JH Horng received a scholarship from TheVax Genetics Vaccine Company. WS Lin is a former employee of TheVax Genetics Vaccine Company. PJ Chen received research funding from TheVax Genetics Vaccine Company. The funding was limited to reimbursement for the necessary expenses for this research work. The other authors have no competing interests to report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}